Patents by Inventor Tamlyn Yee Neben

Tamlyn Yee Neben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies directed against nerve growth factor (NGF)
    Patent number: 9951126
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: April 24, 2018
    Assignee: AnaptysBio, Inc.
    Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben
  • ANTIBODIES DIRECTED AGAINST NERVE GROWTH FACTOR (NGF)
    Publication number: 20150118226
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 30, 2015
    Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben
  • Antibodies directed against nerve growth factor (NGF)
    Patent number: 8926978
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: January 6, 2015
    Assignee: AnaptysBio, Inc.
    Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben